Skip to main content

Table 2 Summary of best overall response

From: Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study

  mITT population (N = 82)
ORR, n (%) 24 (29.3)
 95% CI 19.7, 40.4
VGPR, n (%) 4 (4.9)
PR, n (%) 20 (24.4)
MR, n (%) 8 (9.8)
SD, n (%) 37 (45.1)
PD, n (%) 7 (8.5)
Not estimable, n (%) 6 (7.3)
  1. ORR, the percentage of patients achieving confirmed best response of sCR, CR, VGPR, or PR
  2. CI Confidence interval, mITT Modified intent-to-treat, MR Minimal response, ORR Overall response rate, PD Progressive disease, PR Partial response, SD Stable disease, VGPR Very good partial response